Effect on stroke of different progestagens in low oestrogen dose oral contraceptives

Poulter, NR; Chang, Choon Lan; Farley, Tmm; Marmot, Michael; Meirik, Olav

doi:10.1016/s0140-6736(99)01013-2

Cited by 39 publications

(11 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They already understand the risks of thromboembolism. They should also know that neither second nor third generation pills increase the risk of myocardial infarction among young women,13 and that the risk of stroke is increased by 1 in 24 000 among pill users14 irrespective of the type of pill 15…”

mentioning

confidence: 99%

The third generation pill controversy ("continued")

Drife

2001

BMJ

View full text Add to dashboard Cite

mentioning

confidence: 99%

The third generation pill controversy ("continued")

Drife

2001

BMJ

View full text Add to dashboard Cite

“…In pill-users, the risk of ischaemic stroke among women with hypertension is at least three times that in those without hypertension 5. Data from one case-control study, involving 697 women with ischaemic stroke and 1962 matched controls, suggest that the risk of ischaemic stroke is similar with levonorgestrel-containing pills and desogestrel- or gestodene-containing pills,31 , 32 but this finding needs confirming.…”

Section: Ischaemic Strokementioning

confidence: 99%

“…The incidence of haemorrhagic stroke in women of reproductive age but who are not pregnant is about 5 per 100,000 women per year 32. In women aged under 35 years who do not smoke and are not hypertensive, taking the combined oral contraceptive pill does not appear to increase the risk of haemorrhagic stroke 5.…”

Section: Haemorrhagic Strokementioning

confidence: 99%

Oral contraceptives and cardiovascular risk

2000

DTB

View full text Add to dashboard Cite

In 1992, we advised that "the oral contraceptive of choice for a healthy young woman probably remains a combined preparation containing 30 or 35µg oestrogen and one of the newer progestogens" (i.e. desogestrel, gestodene, norgestimate).1 In 1995, evidence emerged suggesting that combined oral contraceptives containing desogestrel or gestodene were associated with a risk of venous thromboembolism about twice that of pills containing other progestogens,2 and the Committee on Safety of Medicines (CSM) advised that desogestrel- and gestodene-containing pills should be used only by women who were intolerant of other combined oral contraceptives and prepared to accept an increased risk of venous thromboembolism. Following an appeal by the drug manufacturers to the UK Medicines Commission, this advice has been modified to state that, provided women are fully informed of the increased risks, "it should be a matter of clinical judgement and personal choice which type of oral contraceptive should be prescribed".3 Here, we discuss the evidence and events leading to the latest advice, reconsider our previous recommendations, and discuss other cardiovascular problems that may be associated with oral contraceptive pills.

show abstract

“…1 In addition, the risk of hypertension, stroke and myocardial infarction may also be slightly increased in women using OC. [2][3][4] Since 1995, a fierce debate has been going on about the relative risk of 'third-generation' OC compared to second-generation OC on CV disease. Second-generation OC contain levonorgestrel as a progestagen, while third-generation OC contain desogestrel or gestodene.…”

Section: Introductionmentioning

confidence: 99%

“…5 However, the risk of stroke was not found to be different among users of second-and third-generation OC. 3 Moreover, the risk of myocardial infarction was recently reported to be lower in third-generation vs second-generation OC users. 4 In Belgium, the majority of OC users is taking thirdgeneration OC.…”

Section: Introductionmentioning

confidence: 99%

Markers for cardiovascular disease in monozygotic twins discordant for the use of third-generation oral contraceptives

et al. 2003

View full text Add to dashboard Cite

Oral contraceptives (OC) modulate the risk for developing cardiovascular (CV) diseases. The aim of this study was to determine whether the use of third-generation OC has an impact on markers of CV disease in genetically identical women. We performed an intrapair comparison in 27 monozygotic twin pairs, one of whom was taking third-generation OC, whereas the other was not using OC. Biometric parameters were ascertained and conventional and 24-h ambulatory blood pressure (BP) was recorded. A fasting blood sample was taken for the measurement of glucose, insulin, proinsulin, lipids, and insulin-like growth factor binding protein-1 (IGFBP-1). Insulin resistance and b-cell function were calculated by homeostasis model assessment (HOMA). A 24-h urine sample for cortisol was obtained. Third-generation OC use increased 24-h ambulatory systolic and diastolic BP by 5.2 and 3.9 mmHg, respectively (both P ¼ 0.0003). There was no effect on glucose, insulin and proinsulin levels, and on HOMA parameters, but the IGFBP-1 levels were markedly raised (P ¼ 0.0009). The lipid profile showed a 34% increase in triglyceride levels (Po0.0001), but also a 7% increase in HDL-cholesterol levels (P ¼ 0.037). Use of third-generation OC impacts on CV disease markers in young-adult genetically identical women. Some changes are beneficial (increased HDLcholesterol), whereas others may be deleterious (increased BP and triglyceride levels) or have unknown effects at this time (increased IGFBP-1 levels).

show abstract

Effect on stroke of different progestagens in low oestrogen dose oral contraceptives

Cited by 39 publications

References 5 publications

The third generation pill controversy ("continued")

The third generation pill controversy ("continued")

Oral contraceptives and cardiovascular risk

Markers for cardiovascular disease in monozygotic twins discordant for the use of third-generation oral contraceptives

Contact Info

Product

Resources

About